NASDAQ:HZNP Horizon Therapeutics Public - HZNP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. $110.00 +0.21 (+0.19%) (As of 02/3/2023 10:32 AM ET) Add Compare Share Share Today's Range$109.75▼$110.2650-Day Range$78.00▼$113.8052-Week Range$57.84▼$117.49Volume219,857 shsAverage Volume3.63 million shsMarket Capitalization$24.93 billionP/E Ratio45.08Dividend YieldN/APrice Target$111.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Horizon Therapeutics Public MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside1.3% Upside$111.42 Price TargetShort InterestHealthy2.44% of Float Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.62Based on 5 Articles This WeekInsider TradingSelling Shares$11.29 M Sold Last QuarterProj. Earnings Growth28.37%From $4.23 to $5.43 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.60 out of 5 starsMedical Sector98th out of 1,029 stocksPharmaceutical Preparations Industry41st out of 501 stocks 2.1 Analyst's Opinion Consensus RatingHorizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $111.42, Horizon Therapeutics Public has a forecasted upside of 1.3% from its current price of $110.00.Amount of Analyst CoverageHorizon Therapeutics Public has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.44% of the float of Horizon Therapeutics Public has been sold short.Short Interest Ratio / Days to CoverHorizon Therapeutics Public has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Horizon Therapeutics Public has recently decreased by 12.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics Public does not currently pay a dividend.Dividend GrowthHorizon Therapeutics Public does not have a long track record of dividend growth. Previous Next 3.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHorizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Horizon Therapeutics Public is -2.61. Previous Next 2.6 News and Social Media Coverage News SentimentHorizon Therapeutics Public has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Horizon Therapeutics Public this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for HZNP on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics Public insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,285,478.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Horizon Therapeutics Public is held by insiders.Percentage Held by Institutions91.01% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics Public are expected to grow by 28.37% in the coming year, from $4.23 to $5.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics Public is 45.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics Public is 45.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.75.Price to Earnings Growth RatioHorizon Therapeutics Public has a PEG Ratio of 1.70. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics Public has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Horizon Therapeutics Public (NASDAQ:HZNP) StockHorizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.Read More Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Stock News HeadlinesJanuary 30, 2023 | finance.yahoo.comHorizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023January 27, 2023 | finance.yahoo.comRule 15 (c) Announcement – Horizon Therapeutics plcFebruary 3, 2023 | PressReach (Ad)Biotech Stock AlertRead Small Pharma's depression clinical trial results.January 24, 2023 | americanbankingnews.comHorizon Therapeutics Public Limited (NASDAQ:HZNP) Receives $111.00 Average PT from AnalystsJanuary 23, 2023 | finance.yahoo.comRule 17 (b) Announcement – Horizon Therapeutics plcJanuary 18, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient PopulationsJanuary 17, 2023 | finance.yahoo.comHere’s Why Horizon Therapeutics Public Limited Company (HZNP) Surged in Q4January 12, 2023 | finance.yahoo.comRule 2.12 Announcement – Horizon Therapeutics plcFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!January 4, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus ErythematosusJanuary 3, 2023 | finance.yahoo.comRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)December 20, 2022 | finance.yahoo.comIf You Invested $1000 in Horizon Therapeutics a Decade Ago, This is How Much It'd Be Worth NowDecember 20, 2022 | finance.yahoo.comUPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)December 13, 2022 | benzinga.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Horizon Therapeutics Public Limited Co. - HZNPDecember 13, 2022 | finance.yahoo.comForm 8.1 Opening Position Disclosure (Horizon Therapeutics plc)December 12, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Horizon Therapeutics Public Limited CompanyDecember 12, 2022 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Horizon Therapeutics Public Limited Company BuyoutDecember 12, 2022 | msn.comHere's How Much $100 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth TodayDecember 12, 2022 | seekingalpha.comWhat Amgen Is Getting Through The Acquisition Of Horizon TherapeuticsDecember 12, 2022 | finance.yahoo.comCentral bank week, Amgen-Horizon deal, Rivian - what's moving marketsDecember 12, 2022 | finance.yahoo.comThese 2 Nasdaq Stocks Are Soaring on Merger NewsDecember 12, 2022 | finance.yahoo.comAmgen Agrees to Acquire Horizon Therapeutics for $27.8 BillionDecember 12, 2022 | finance.yahoo.comHorizon Therapeutics Stock Jumps on Amgen Deal NewsDecember 12, 2022 | finance.yahoo.comAmgen to buy Horizon Therapeutics, Shein mulls becoming a marketplace, U.S. to announce nuclear breakthroughDecember 12, 2022 | finance.yahoo.comAmgen to buy Horizon Therapeutics for $28 billion cashDecember 12, 2022 | finance.yahoo.comWhy Horizon Therapeutics Stock Is Soaring TodayDecember 12, 2022 | finance.yahoo.comAmgen to acquire Horizon Therapeutics for $27.8 billionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Company Calendar Last Earnings11/03/2021Today2/03/2023Next Earnings (Confirmed)3/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees1,890Year Founded2008Price Target and Rating Average Stock Price Forecast$111.42 High Stock Price Forecast$144.00 Low Stock Price Forecast$71.00 Forecasted Upside/Downside+1.3%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.44 Trailing P/E Ratio45.08 Forward P/E Ratio26.00 P/E Growth1.7Net Income$534.49 million Net Margins15.51% Pretax Margin15.77% Return on Equity24.59% Return on Assets13.56% Debt Debt-to-Equity Ratio0.51 Current Ratio3.96 Quick Ratio3.74 Sales & Book Value Annual Sales$3.23 billion Price / Sales7.73 Cash Flow$6.41 per share Price / Cash Flow17.15 Book Value$20.60 per share Price / Book5.34Miscellaneous Outstanding Shares226,620,000Free Float220,955,000Market Cap$24.93 billion OptionableOptionable Beta1.15 Social Links Key ExecutivesTimothy P. WalbertChairman, President & Chief Executive OfficerAaron L. CoxChief Financial Officer & Executive Vice PresidentJeffrey W. ShermanChief Medical Officer & Executive Vice PresidentJeffrey D. KentExecutive VP-Medical Affairs & Outcomes ResearchMichael A. DesJardinExecutive VP-Technical Operations & QualityKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZZoetisNYSE:ZTSGenmab A/SNASDAQ:GMABBeiGeneNASDAQ:BGNEAlnylam PharmaceuticalsNASDAQ:ALNYView All CompetitorsInsiders & InstitutionsProfund Advisors LLCBought 156 shares on 2/2/2023Ownership: 0.011%ProShare Advisors LLCSold 870 shares on 2/2/2023Ownership: 0.010%Von Berge Wealth Management Group LLCBought 490 shares on 2/2/2023Ownership: 0.002%Legacy Wealth Asset Management LLCSold 167 shares on 2/2/2023Ownership: 0.001%Raymond James Trust N.A.Bought 1,794 shares on 2/2/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions HZNP Stock - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. What is Horizon Therapeutics Public's stock price forecast for 2023? 11 brokerages have issued 1-year price targets for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they expect the company's share price to reach $111.42 in the next year. This suggests a possible upside of 1.3% from the stock's current price. View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts. How have HZNP shares performed in 2023? Horizon Therapeutics Public's stock was trading at $113.80 on January 1st, 2023. Since then, HZNP shares have decreased by 3.4% and is now trading at $109.98. View the best growth stocks for 2023 here. When is Horizon Therapeutics Public's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023. View our HZNP earnings forecast. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.54 by $0.21. The biopharmaceutical company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $979.49 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 24.59% and a net margin of 15.51%. The firm's revenue for the quarter was up 62.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.74 EPS. What guidance has Horizon Therapeutics Public issued on next quarter's earnings? Horizon Therapeutics Public updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.59 billion-$3.61 billion, compared to the consensus revenue estimate of $3.56 billion. What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). What is Horizon Therapeutics Public's stock symbol? Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP." Who are Horizon Therapeutics Public's major shareholders? Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.58%), Bank of Montreal Can (0.36%), Strs Ohio (0.31%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Allspring Global Investments Holdings LLC (0.18%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel. View institutional ownership trends. How do I buy shares of Horizon Therapeutics Public? Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Horizon Therapeutics Public's stock price today? One share of HZNP stock can currently be purchased for approximately $109.98. How much money does Horizon Therapeutics Public make? Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $24.92 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $2.44 on an earnings per share basis. How many employees does Horizon Therapeutics Public have? The company employs 1,890 workers across the globe. Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More How can I contact Horizon Therapeutics Public? Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001. This page (NASDAQ:HZNP) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.